Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 11, 2001, Pages 604-612

  Dey, B R ^a   McAfee, S ^a   Sackstein, R ^a   Colby, C ^a   Saidman, S ^a   Weymouth, D ^a   Poliquin, C ^a   Vanderklish, J ^a   Sachs, D H ^a   Sykes, M ^a   Spitzer, T R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Donor leukocyte infusion; Graft versus tumor effect; Mixed chimerism; Nonmyeloablative conditioning; Stem cell transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; EVALUATION; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HLA MATCHING; HODGKIN DISEASE; HUMAN; IRRADIATION; LEUKOCYTE; MULTIPLE MYELOMA; PROBABILITY; SALVAGE THERAPY; STATISTICS; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TIME PERCEPTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0035203625     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11760148     Document Type: Article

References (48)

1. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
2. Bone marrow transplantation
3. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease
4. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma
5. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen
6. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
7. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
8. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
9. Role of a second transplant in the management of poor-prognosis lymphomas: A report from the European Blood and Bone Marrow Registry
10. Bone marrow transplantation after failure of autologous transplantation for non-Hodgkin's lymphoma
11. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?
12. Second allogeneic transplantation after failure of first autologous transplantation
13. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts
14. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen
15. Mixed allogeneic chimerism and renal allograft tolerance in cynomologous monkeys
16. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacologic immunosuppression after bone marrow transplantation
17. Induction of high levels of allogeneic hematopoietic reconstitution and donor specific tolerance without myelosuppressive conditioning
18. Graft-versus-host-related immunosuppression induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells
19. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease
20. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease Bone
21. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets
22. Transplantation tolerance in adult rats using total lymphoid irradiation: Permanent survival of skin, heart, and marrow allografts
23. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease
24. Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay
25. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: A stable equilibrium
26. Mixed chimerism after allogeneic bone marrow transplantation for leukemia: Correlation with dose of total body irradiation and graft-versus-host disease
27. Evolution of mixed chimerism after allogeneic bone marrow transplantation as determined on granulocytes and mononuclear cells by the polymerase chain reaction
28. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation
29. Effect of radiation on the development of mixed haemopoietic chimerism following T cell-depleted allogeneic bone marrow transplantation
30. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia
31. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies
32. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation
33. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies
34. Regimen-related toxicity in patients undergoing bone marrow transplantation
35. Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy
36. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up
37. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse
38. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation
39. Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation
40. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease
41. Natural history of HLA expression during tumour development
42. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
43. Expression of costimulatory molecules in human leukemias
44. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation
45. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
46. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
47. Mixed allogeneic chimeras prepared by a non-myeloablative regimen: Requirement for chimerism to maintain tolerance
48. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study